Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Moderna COVID-19 Shot Lowers Risk Of Infection, Hospitalization Compared To Pfizer's, VA Real-World Data Shows

A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc's (NYSE:PFE) COVID-19 vaccine, Moderna Inc (NASDAQ:MRNA) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations.

  • Lower risk was observed across all age groups, comorbidity-burden categories, and race.
  • Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer's BNT162b2 "in risk of infection or hospitalization were progressively greater when the follow-up period was longer."
  • Related: Pfizer's Omicron-Targeted Vaccine Expected To Be Ready In March: CEO Says On CNBC.
  • The study evaluated over 900,000 vaccine recipients, followed for a mean of 192 days, during which there were almost 17,000 infections, more than 3,500 hospitalizations, and 381 deaths.
  • While fewer patients who received Moderna's vaccine died than Pfizer (168 versus 213), the researchers said this difference was not statistically significant.
  • Price Action: PFE stock is up 0.17% at $56.32, MRNA stock is down 4.63% at $222.88 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.